Stockreport

FDA grants breakthrough therapy status for Nuvalent's NVL-655 [Yahoo! Finance]

Nuvalent, Inc. - Class A  (NUVL) 
NASDAQ:AMEX Investor Relations: nuvelinc.com/company/investor_relations.html
PDF kinase (ALK)-selective tyrosine kinase inhibitor (TKI), NVL-655 for the treatment of non-small cell lung cancer (NSCLC). NVL-655 is intended to treat patients with loc [Read more]